Call it a decisive move to expand its footprint in women’s health.

 

Pharma powerhouse Dr Reddy’s Laboratories has acquired the trademarks and related assets of specialty brands Progynova and Cyclo-Progynova in India from Mercury Pharma Group.

 

The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India.

 

Progynova (estradiol valerate) is an oral hormone replacement therapy used to treat estrogen deficiency symptoms and prevent postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined therapy designed to treat estrogen deficiency symptoms while providing both estrogen and progestogen components.

 

Progynova currently ranks as the #1 brand in the Estradiol represented pharmaceutical market (RPM) in India, backed by strong physician trust and brand recall. According to IQVIA MAT December 2025 data, the brand recorded sales of INR 100 crore.

 

The deal positions Dr. Reddy’s to accelerate its presence in a critical therapeutic segment amid rising awareness and demand for menopause-related treatments.

 

MV Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy’s, said: “The acquisition will serve as the spearhead of our expansion into the HRT segment, strengthening our existing gynaecology portfolio in India."

 

"With our established market access, we are uniquely positioned to extend the reach of the acquired assets and deliver greater impact. Furthermore, this acquisition brings a first-in-class treatment closer to patients, underscoring our commitment to innovation and patient care at the centre of everything we do.”

 

With this latest acquisition, Dr Reddy’s signals its intent to play a larger role in addressing women’s health needs in India — and to compete aggressively in the evolving HRT landscape.